Logo image of MEDP

MEDPACE HOLDINGS INC (MEDP) Stock Fundamental Analysis

NASDAQ:MEDP - Nasdaq - US58506Q1094 - Common Stock - Currency: USD

350.04  +7.02 (+2.05%)

After market: 350.04 0 (0%)

Fundamental Rating

7

Overall MEDP gets a fundamental rating of 7 out of 10. We evaluated MEDP against 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make MEDP a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year MEDP was profitable.
In the past year MEDP had a positive cash flow from operations.
In the past 5 years MEDP has always been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
MEDP Yearly Net Income VS EBIT VS OCF VS FCFMEDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

1.2 Ratios

The Return On Assets of MEDP (17.54%) is better than 98.25% of its industry peers.
MEDP has a better Return On Equity (41.47%) than 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 33.52%, MEDP belongs to the best of the industry, outperforming 98.25% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MEDP is significantly above the industry average of 9.61%.
The 3 year average ROIC (31.51%) for MEDP is below the current ROIC(33.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.54%
ROE 41.47%
ROIC 33.52%
ROA(3y)15.37%
ROA(5y)13.06%
ROE(3y)44.35%
ROE(5y)32.97%
ROIC(3y)31.51%
ROIC(5y)24.63%
MEDP Yearly ROA, ROE, ROICMEDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

1.3 Margins

MEDP has a better Profit Margin (17.65%) than 92.98% of its industry peers.
In the last couple of years the Profit Margin of MEDP has grown nicely.
Looking at the Operating Margin, with a value of 19.74%, MEDP belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
In the last couple of years the Operating Margin of MEDP has grown nicely.
Looking at the Gross Margin, with a value of 29.69%, MEDP is doing worse than 70.18% of the companies in the same industry.
In the last couple of years the Gross Margin of MEDP has declined.
Industry RankSector Rank
OM 19.74%
PM (TTM) 17.65%
GM 29.69%
OM growth 3Y-0.33%
OM growth 5Y4.5%
PM growth 3Y-1.43%
PM growth 5Y7.69%
GM growth 3Y-2.6%
GM growth 5Y-1.88%
MEDP Yearly Profit, Operating, Gross MarginsMEDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
MEDP has less shares outstanding than it did 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEDP Yearly Shares OutstandingMEDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
MEDP Yearly Total Debt VS Total AssetsMEDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 7.00 indicates that MEDP is not in any danger for bankruptcy at the moment.
The Altman-Z score of MEDP (7.00) is better than 85.96% of its industry peers.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7
ROIC/WACC3.25
WACC10.31%
MEDP Yearly LT Debt VS Equity VS FCFMEDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 0.99 indicates that MEDP may have some problems paying its short term obligations.
MEDP has a Current ratio of 0.99. This is amonst the worse of the industry: MEDP underperforms 89.47% of its industry peers.
A Quick Ratio of 0.99 indicates that MEDP may have some problems paying its short term obligations.
MEDP's Quick ratio of 0.99 is on the low side compared to the rest of the industry. MEDP is outperformed by 80.70% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.99
MEDP Yearly Current Assets VS Current LiabilitesMEDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.72% over the past year.
The Earnings Per Share has been growing by 27.94% on average over the past years. This is a very strong growth
MEDP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.24%.
The Revenue has been growing by 21.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)33.72%
EPS 3Y31.33%
EPS 5Y27.94%
EPS Q2Q%35.59%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y26.76%
Revenue growth 5Y21.76%
Sales Q2Q%8.29%

3.2 Future

The Earnings Per Share is expected to grow by 16.08% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.23% on average over the next years. This is quite good.
EPS Next Y37.19%
EPS Next 2Y20.07%
EPS Next 3Y18.33%
EPS Next 5Y16.08%
Revenue Next Year11.75%
Revenue Next 2Y8.67%
Revenue Next 3Y9.81%
Revenue Next 5Y11.23%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
MEDP Yearly Revenue VS EstimatesMEDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
MEDP Yearly EPS VS EstimatesMEDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.65, the valuation of MEDP can be described as expensive.
MEDP's Price/Earnings ratio is a bit cheaper when compared to the industry. MEDP is cheaper than 78.95% of the companies in the same industry.
MEDP's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.51.
With a Price/Forward Earnings ratio of 27.34, MEDP can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, MEDP is valued a bit cheaper than the industry average as 77.19% of the companies are valued more expensively.
MEDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 93.88, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 30.65
Fwd PE 27.34
MEDP Price Earnings VS Forward Price EarningsMEDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

MEDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MEDP is cheaper than 85.96% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDP indicates a rather cheap valuation: MEDP is cheaper than 91.23% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 20.31
EV/EBITDA 22.86
MEDP Per share dataMEDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

MEDP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MEDP has an outstanding profitability rating, which may justify a higher PE ratio.
MEDP's earnings are expected to grow with 18.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)1.1
EPS Next 2Y20.07%
EPS Next 3Y18.33%

More info and screens

0

5. Dividend

5.1 Amount

MEDP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDPACE HOLDINGS INC

NASDAQ:MEDP (1/30/2025, 5:20:00 PM)

After market: 350.04 0 (0%)

350.04

+7.02 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-21 2024-10-21/amc
Earnings (Next)02-10 2025-02-10/amc
Inst Owners85.75%
Inst Owner Change-1.14%
Ins Owners0.41%
Ins Owner Change1.27%
Market Cap10.88B
Analysts75
Price Target360.77 (3.07%)
Short Float %4.53%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.24%
Min EPS beat(2)6.19%
Max EPS beat(2)6.29%
EPS beat(4)4
Avg EPS beat(4)12.07%
Min EPS beat(4)6.19%
Max EPS beat(4)27.27%
EPS beat(8)7
Avg EPS beat(8)11.68%
EPS beat(12)11
Avg EPS beat(12)14.48%
EPS beat(16)15
Avg EPS beat(16)13.41%
Revenue beat(2)0
Avg Revenue beat(2)-2.7%
Min Revenue beat(2)-3.35%
Max Revenue beat(2)-2.06%
Revenue beat(4)0
Avg Revenue beat(4)-2.42%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)-2.02%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)6
Avg Revenue beat(12)0.37%
Revenue beat(16)8
Avg Revenue beat(16)0.23%
PT rev (1m)0%
PT rev (3m)-7.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.92%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.6%
Valuation
Industry RankSector Rank
PE 30.65
Fwd PE 27.34
P/S 5.25
P/FCF 20.31
P/OCF 18.94
P/B 12.34
P/tB 59.02
EV/EBITDA 22.86
EPS(TTM)11.42
EY3.26%
EPS(NY)12.8
Fwd EY3.66%
FCF(TTM)17.24
FCFY4.92%
OCF(TTM)18.49
OCFY5.28%
SpS66.63
BVpS28.36
TBVpS5.93
PEG (NY)0.82
PEG (5Y)1.1
Profitability
Industry RankSector Rank
ROA 17.54%
ROE 41.47%
ROCE 39.21%
ROIC 33.52%
ROICexc 90.59%
ROICexgc N/A
OM 19.74%
PM (TTM) 17.65%
GM 29.69%
FCFM 25.87%
ROA(3y)15.37%
ROA(5y)13.06%
ROE(3y)44.35%
ROE(5y)32.97%
ROIC(3y)31.51%
ROIC(5y)24.63%
ROICexc(3y)42.48%
ROICexc(5y)32.99%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)38.27%
ROCE(5y)29.66%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y40.79%
ROICexc growth 5Y36.37%
OM growth 3Y-0.33%
OM growth 5Y4.5%
PM growth 3Y-1.43%
PM growth 5Y7.69%
GM growth 3Y-2.6%
GM growth 5Y-1.88%
F-Score6
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 135.03%
Cap/Sales 1.88%
Interest Coverage 250
Cash Conversion 131.29%
Profit Quality 146.53%
Current Ratio 0.99
Quick Ratio 0.99
Altman-Z 7
F-Score6
WACC10.31%
ROIC/WACC3.25
Cap/Depr(3y)146.02%
Cap/Depr(5y)134.98%
Cap/Sales(3y)2.32%
Cap/Sales(5y)2.48%
Profit Quality(3y)137.72%
Profit Quality(5y)150.74%
High Growth Momentum
Growth
EPS 1Y (TTM)33.72%
EPS 3Y31.33%
EPS 5Y27.94%
EPS Q2Q%35.59%
EPS Next Y37.19%
EPS Next 2Y20.07%
EPS Next 3Y18.33%
EPS Next 5Y16.08%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y26.76%
Revenue growth 5Y21.76%
Sales Q2Q%8.29%
Revenue Next Year11.75%
Revenue Next 2Y8.67%
Revenue Next 3Y9.81%
Revenue Next 5Y11.23%
EBIT growth 1Y25.44%
EBIT growth 3Y26.35%
EBIT growth 5Y27.24%
EBIT Next Year38.56%
EBIT Next 3Y17.55%
EBIT Next 5Y17.1%
FCF growth 1Y87.56%
FCF growth 3Y20.38%
FCF growth 5Y23.06%
OCF growth 1Y78.26%
OCF growth 3Y18.77%
OCF growth 5Y22.58%